Remove Documentation Remove Events Remove Immunization
article thumbnail

Deucravacitinib Shows Joint, Skin Symptom Improvements in Psoriatic Arthritis

Drug Topics

The study cohort included 670 patients who were diagnosed with PsA of at least a 3 month duration and have active plaque psoriatic skin lesions or a documented medical history of plaque psoriasis. The most frequent adverse event in both groups was upper respiratory tract infection. of patients who received placebo.

article thumbnail

Significant Knowledge Gap Exists in Patient Awareness of Psoriatic Disease

Drug Topics

1 “Psoriasis is a chronic disease in which the immune system becomes overactive, causing skin cells to multiply too quickly,” wrote the National Institute of Arthritis and Musculoskeletal and Skin Diseases. This led researchers to explore a specific region of the world in order to better document patients’ understanding of the disease.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Immunotherapy Takes the Lead in Advanced Cutaneous Malignancies

Pharmacy Times

Have you observed these immune-related toxicities in your practice, and if so, how are they being managed? All patients should have immunotherapy first. Pharmacy Times : As immunotherapies expand into the solid tumor space, clinicians are reporting cases of ICANS and CRS. It was approved last year.

65
article thumbnail

Dupixent face rash and redness: Causes and treatment

The Checkup by Singlecare

How Dupixent works in the body It’s still unclear what causes atopic dermatitis , the most common form of adult and pediatric eczema, but it’s commonly regarded as an immune system and skin barrier condition. Those intruders trigger the immune system, which releases certain proteins that cause skin inflammation.

article thumbnail

Five for Friday September 22: Celebrating Success in Advancing Medication Use Quality

PQA

We continue to play a central role in driving meaningful improvements and positive changes related to medication safety, adherence and appropriate use.The 2023 PQA Annual Report documents our progress towards Blueprint PQA 2025. These events is an invitation-only event for PQA member organization leaders.

article thumbnail

The future of medical cannabis development in Europe

European Pharmaceutical Review

5 These compounds have been shown in pre-clinical studies to have an array of potential effects on the immune, nervous, cardiovascular, respiratory and endocrine systems. Cannabis complications There are notable complexities to researching medical cannabis using a linear approach to clinical translation.

article thumbnail

Sanofi offers refunds for Cablivi in novel model for rebates

Pharmaceutical Technology

The program follows the lead of Pfizer’s warranty programs for Panzyga (immune globulin intravenous) and Xalkori (crizotinib), as pharma continues to explore new types of risk sharing agreements. Cablivi stops platelets from clumping together, which prevents small clots, and can be used along with other drugs that suppress the immune system.